CA
HAE icon

CoreCap Advisors’s Haemonetics HAE Stock Holding History

CoreCap Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
+2
New +$128 ﹤0.01% 3040
2025
Q2 		– Sell
-3
Closed -$191 – 2954
2025
Q1 		$191 Buy
+3
New +$204 ﹤0.01% 2991
2024
Q4 		– Sell
-547
Closed -$44K – 2910
2024
Q3 		$44K Buy
+547
New +$44.2K ﹤0.01% 1241
2024
Q2 		– Sell
-783
Closed -$66.8K – 2009
2024
Q1 		$66.8K Buy
+783
New +$61.4K ﹤0.01% 1000
2022
Q4 		$70.2K Buy
+892
New +$71.7K 0.01% 864
2022
Q1 		– Sell
-4
Closed -$1K – 1166
2021
Q4 		$1K Buy
+4
New +$244 ﹤0.01% 2133

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's HAE Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Haemonetics (HAE) in Q2 2026: 2 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #3040 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in HAE as recently as Q1 2025.

CoreCap Advisors first reported a position in HAE in Q4 2021 and has held it in 6 quarters since. The position peaked at $70.2K in Q4 2022. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • CoreCap Advisors held 2 shares of Haemonetics worth $150 as of Q2 2026.
  • Haemonetics was a new CoreCap Advisors position in Q2 2026.
  • Haemonetics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3040 holding.
  • CoreCap Advisors first reported a position in Haemonetics in Q4 2021 and has held it in 6 quarters since.
  • CoreCap Advisors's Haemonetics position peaked at $70.2K in Q4 2022.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.